In the field of synthetic biology, the company will continue to explore the D-ribose market and expand its market share. The company will strive to increase the market share of D-ribose terminal products. In 2025, Chengzhi will continue to promote the construction of the Jiangxi Chengzhi Biological Raw Material Drug Workshop project, while also advancing the construction of the Hanmeng project Chengzhi's goal for this year is to expand its product structure and strive to increase the proportion of raw material products with higher added value.
Chengzhi will rely on the Yingtan factory to build a high-level advanced biomanufacturing platform and synthetic biotechnology innovation base, and rely on the Chengzhi Hanmeng digital intelligence factory to build a high-value utilization and potential pharmaceutical platform for plant extraction. The company deepens its internal business and promotes collaborative development from the research and development, production, and sales ends. The company will actively explore cooperation models, continue to deepen cooperation with universities and research institutes, continuously strengthen applied research in the field of synthetic biology, and collaborate to promote inward investment and outward mergers and acquisitions. In the end, the company will fill the gaps in competition, extend the industrial chain, and build a synthetic biology business sector with more comprehensive competitive strength.
In the future, Chengzhi Group will continue to steadfastly implement the overall development strategy of "one body, two wings", further strengthen the company's existing resource allocation, form a higher quality industrial cluster effect, and lay a solid foundation for the company's development into an international enterprise.

